Increased anti-P-glycoprotein activity of baicalein by alkylation on the A ring

Journal of Medicinal Chemistry

Volumn 47, Issue 22, 2004, Pages 5555-5566

  Lee, Yashang ^a   Yeo, Hosup ^a,b   Liu, Shwu Huey ^c   Jiang, Zaoli ^c   Savizky, Ruben M ^b   Austin, David J ^b   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c PhytoCeutica Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHOXY 6,7 DIPROPYLOXYFLAVONE; BAICALEIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; UNCLASSIFIED DRUG; VINBLASTINE;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL GROWTH; DRUG ACCUMULATION; DRUG ACETYLATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; STRUCTURE ACTIVITY RELATION;

ALKYLATION; CELL LINE; CELL PROLIFERATION; DRUG RESISTANCE, MULTIPLE; DRUGS, CHINESE HERBAL; FLAVANONES; HUMANS; P-GLYCOPROTEIN; SCUTELLARIA BAICALENSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 6044224896     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049949c     Document Type: Article

References (39)

1. Germann, U. A. P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur. J. Cancer 1996, 32A, 927-944.
2. Gottesman, M. M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 1993, 62, 385-427.
3. Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M. M.; Pastan, I. et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 7735-7738.
4. Borst, P.; Schinkel, A. H. What have we learnt thus far from mice with disrupted P-glycoprotein genes? Eur. J. Cancer 1996, 32A, 985-990.
5. Luker, G. D.; Nilsson, K. R.; Covey, D. F.; Piwnica-Worms, D. Multidrug resistance (MDR1) P-glycoprotein enhances esterification of plasma membrane cholesterol. J. Biol. Chem. 1999, 274, 6979-6991.
6. Dalton, W. S.; Grogan, T. M.; Meltzer, P. S.; Scheper, R. J.; Durie, B. G. et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol. 1989, 7, 415-424.
7. Miller, T. P.; Grogan, T. M.; Dalton, W. S.; Spier, C. M.; Scheper, R. J. et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J. Clin. Oncol. 1991, 9, 17-24.
8. Nuessler, V.; Scheulen, M. E.; Oberneder, R.; Kriegmair, M.; Goebel, K. J. et al. Phase I and pharmacokinetic study of the P-glycoprotein modulator dexniguldipine-HCL. Eur. J. Med. Res. 1997, 2, 55-61.
9. Wilson, W. H.; Jamis-Dow, C.; Bryant, G.; Balis, F. M.; Klecker, R. W. et al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J. Clin. Oncol. 1995, 13, 1985-1994.
10. Hyafil, F.; Vergely, C.; Du Vignaud, P.; Grand-Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993, 53, 4595-4602.
11. Boesch, D.; Gaveriaux, C.; Jachez, B.; Pourtier-Manzanedo, A.; Bollinger, P. et al. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 1991, 51, 4226-4233.
12. Ramu, A.; Spanier, R.; Rahamimoff, H.; Fuks, Z. Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells. Br. J. Cancer 1984, 50, 501-507.
13. Middleton, E., Jr.; Kandaswami, C.; Theoharides, T. C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol. Rev. 2000, 52, 673-751.
14. Bailey, D. G.; Malcolm, J.; Arnold, O.; Spence, J. D. Grapefruit juice-drug interactions. Br. J. Clin. Pharmacol. 1998, 46, 101-110.
15. Ducharme, M. P.; Warbasse, L. H.; Edwards, D. J. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin. Pharmacol. Ther. 1995, 57, 485-491.
16. De Vincenzo, R.; Scambia, G.; Benedetti Panici, P.; Ranelletti, F. O.; Bonanno, G. et al. Effect of synthetic and naturally occurring chalcones on ovarian cancer cell growth: structure-activity relationships. Anticancer Drug Des. 1995, 10, 481-490.
17. Murakami, S.; Muramatsu, M.; Tomisawa, K. Inhibition of gastric H+, K(+)-ATPase by flavonoids: a structure-activity study. J. Enzyme Inhib. 1999, 14, 151-166.
18. Akiyama, T.; Ishida, J.; Nakagawa, S.; Ogawara, H.; Watanabe, S. et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 1987, 262, 5592-5595.
19. De Azevedo, W. F., Jr.; Mueller-Dieckmann, H. J.; Schulze-Gahmen, U.; Worland, P. J.; Sausville, E. et al. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 2735-2740.
20. Boumendjel, A.; Di Pietro, A.; Dumontet, C.; Barron, D. Recent advances in the discovery of flavonoids and analogues with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med. Res. Rev. 2002, 22, 512-529.
21. Efferth, T.; Davey, M.; Olbrich, A.; Rucker, G.; Gebhart, E. et al. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol. Dis. 2002, 28, 160-168.
22. Conseil, G.; Baubichon-Cortay, H.; Dayan, G.; Jault, J. M.; Barron, D. et al. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 9831-9836.
23. Perez-Victoria, J. M.; Perez-Victoria, F. J.; Conseil, G.; Maitre-jean, M.; Comte, G. et al. High-affinity binding of silybin derivatives to the nucleotide-binding domain of a Leishmania tropica P-glycoprotein-like transporter and chemosensitization of a multidrug-resistant parasite to daunomycin. Antimicrob Agents Chemother 2001, 45, 439-446.
24. Thiyagarajah, P.; Kuttan, S. C.; Lim, S. C.; Teo, T. S.; Das, N. P. Effect of myricetin and other flavonoids on the liver plasma membrane Ca2+ pump. Kinetics and structure-function relationships. Biochem. Pharmacol. 1991, 41, 669-675.
25. Hirano, T.; Oka, K.; Akiba, M. Effects of synthetic and naturally occurring flavonoids on Na+, K+-ATPase: aspects of the structure-activity relationship and action mechanism. Life Sci. 1989, 45, 1111-1117.
26. Jinsart, W.; Ternai, B.; Polya, G. M. Inhibition of rat liver cyclic AMP-dependent protein kinase by flavonoids. Biol. Chem. Hoppe Seyler 1992, 373, 205-211.
27. Ferriola, P. C.; Cody, V.; Middleton, E., Jr. Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms and structure-activity relationships. Biochem. Pharmacol. 1989, 38, 1617-1624.
28. Hagiwara, M.; Inoue, S.; Tanaka, T.; Nunoki, K.; Ito, M. et al. Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonine protein kinases. Biochem. Pharmacol. 1988, 37, 2987-2992.
29. Perez-Victoria, J. M.; Chiquero, M. J.; Conseil, G.; Dayan, G.; Di Pietro, A. et al. Correlation between the affinity of flavonoids binding to the cytosolic site of Leishmania tropica multidrug transporter and their efficiency to revert parasite resistance to daunomycin. Biochemistry 1999, 38, 1736-1743.
30. Lo, A.; Burckart, G. J. P-glycoprotein and drug therapy in organ transplantation. J. Clin. Pharmacol. 1999, 39, 995-1005.
31. Wang, R. B.; Kuo, C. L.; Lien, L. L.; Lien, E. J. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J. Clin. Pharm. Ther. 2003, 28, 203-228.
32. Di Pietro, A.; Conseil, G.; Perez-Victoria, J. M.; Dayan, G.; Baubichon-Cortay, H. et al. Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol. Life Sci. 2002, 59, 307-322.
33. Chambers, T. C.; Pohl, J.; Raynor, R. L.; Kuo, J. F. Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C. J. Biol. Chem. 1993, 268, 4592-4595.
34. Callaghan, R.; Higgins, C. F. Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br. J. Cancer 1995, 71, 294-299.
35. Smith, C. D.; Zilfou, J. T. Circumvention of P-glycoprotein-mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. J. Biol. Chem. 1995, 270, 28145-28152.
36. Conseil, G.; Perez-Victoria, J. M.; Jault, J. M.; Gamarro, F.; Goffeau, A. et al. Protein kinase C effectors bind to multidrug ABC transporters and inhibit their activity. Biochemistry 2001, 40, 2564-2571.
37. Dayan, G.; Jault, J. M.; Baubichon-Cortay, H.; Baggetto, L. G.; Renoir, J. M. et al. Binding of steroid modulators to recombinant cytosolic domain from mouse P-glycoprotein in close proximity to the ATP site. Biochemistry 1997, 36, 15208-15215.
38. Chen, H. X.; Bamberger, U.; Heckel, A.; Guo, X.; Cheng, Y. C. BIBW 22, a dipyridamole analogue, acts as a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleoside transport. Cancer Res. 1993, 53, 1974-1977.
39. Park, S. Y.; Lam, W.; Cheng, Y. C. X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res. 2002, 62, 459-465.